Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in acute traumatic cervical spinal cord injury
NCT04295538Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of elezanumab in spinal cord injury (SCI), sponsored by AbbVie Inc.. Started Sep 2020; status: completed.
02
Drugs
elezanumab
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04295538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295538.